Published technology appraisals from the National Institute for Health and Clinical Excellence (NICE) have decisions which are grouped into three categories:
where the treatment(s) is recommended for routine use in the national health service;
where the treatment(s) is recommended for selective use in the NHS (i.e. for certain patients, after other treatments have failed etc); and
where the treatment(s) is recommended for use in research only or is not recommended.
The following table lists all the technology appraisals relating to cancer treatments published by NICE to the end of June 2007, including the date of referral, the condition and the drugs appraised, the date the guidance was published, the number of the appraisal (TA#) and the decision.
TA# Condition and drugs appraised Referral date Publication Recommendation 3 ovarian cancer—paclitaxel (Taxol) 4 November 1999 May 2000 Selective 6 breast cancer—docetaxel (Taxotere), paclitaxel (Taxol) 4 November 1999 June 2000 Selective 23 recurrent malignant glioma—temozolomide (Temodal) 12 July 2000 April 2001 Selective 25 pancreatic cancer gemcitabine (Gemzar) 12 July 2000 May 2001 Selective 26 lung cancer (non-small cell)—paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), vinorelbine (Navelbine) 12 July 2000 June 2001 Routine 28 ovarian cancer (advanced)—topetecan (Hycamtin) 12 July 2000 August 2001 Selective 29 chronic lymphocytic leukaemia—fludarabine (Fludara) 12 July 2000 September 2001 Routine 30 breast cancer—docetaxel (Taxotere), paclitaxel (Taxol) Review of TA06 12 July 2000 September 2001 Selective 33 colorectal cancer (advanced)—irinotecan (Campto), oxaliplatin (Eloxatin), raltitrexed (Tomudex) 12 July 2000 March 2002 Selective 34 breast cancer (advanced)—tratuzumab (Herceptin) 12 July 2000 March 2002 Selective 37 non-Hodgkin's lymphoma—rituximab (MabThera) 12 July 2000 March 2002 Selective 45 ovarian cancer—pegylated liposomal doxorubicin hydrochloride (Caelyx) 12 March 2001 July 2002 Selective 50 chronic myeloid leukaemia—imatinib (Glivec) 12 March 2001 September 2002 Routine 54 breast cancer (advanced)—vinorelbine (Navelbine) 12 July 2000 December 2002 Selective 55 ovarian cancer—paclitaxel (Taxol) Review of TA03 12 July 2000 January 2003 Routine 61 colorectal cancer (Metastatic)—capecitabine (Xeloda), tegafur with uracil (Uftoral) 31 July 2001 May 2003 Routine 62 breast cancer (locally advanced)—capecitabine (Xeloda) 31 July 2001 May 2003 Routine 65 aggressive non-Hodgkin's lymphoma—rituximab (MabThera) 20 May 2002 September 2003 Selective 70 chronic myeloid leukaemia—imatinib (Glivec) Review of TA50 20 May 2002 October 2003 Selective 86 gastro-intestinal stromal tumours (GIST)—imatinib (Glivec) 31 March 2003 October 2004 Selective 91 ovarian cancer (advanced)—paclitaxel (Taxol), pegylated liposomal doxorubicin hydrochloride (Caelyx), topotecan (Hycamtin) Review of TA28, TA45 and TA55 May 2005 Selective 93 colorectal cancer (advanced)—irinotecan (Campto), oxaliplatin (Eloxatin), raltitrexed (Tomudex) Review of TA33 1 April 2005 August 2005 Selective 100 colon cancer (adjuvant)—oxaliplatin (Eloxatin), capecitabine (Xeloda) 21 June 2004 April 2006 Routine 101 prostate cancer (hormone refractory)—docetaxel (Taxotere) 21 June 2004 June 2006 Routine 107 breast cancer (early)—trastuzumab (Herceptin) 21 July 2005 (transferred to STA programme November 2005). Licence granted for use in early breast cancer May 2006 August 2006 Selective 108 breast cancer (early)—paclitaxel (Taxol) 5 April 2005 (transferred to STA programme November 2005) September 2006 Not recommended 109 breast cancer (early)—docetaxel (Taxotere) 5 April 2005 (transferred to STA programme November 2005) September 2006 Routine 110 follicular lymphoma—rituximab (MabThera) 5 April 2005 (transferred to STA programme November 2005) September 2006 Routine 112 breast cancer (early)—anastrozole (Arimidex), exemestane (Aromasin), letrozole (Femara) 21 June 2004 November 2006 Routine 116 metastatic breast cancer—gemcitabine (Gemzar) 5 April 2005 (transferred to STA programme November 2005) January 2007 Selective 118 metastatic colorectal cancer—bevacizumab (Avastin) and cetuximab (Erbitux) 21 June 2004 January 2007 Not recommended 119 chronic lymphocytic leukaemia—fludarabine (Fludara) Review of TA29 5 April 2005 (transferred to STA programme November 2005. Deferred July 2006 awaiting Medical Research Council trial) February 2007 Not recommended 121 glioma (newly diagnosed and high grade)—carmustine implants (Gliadel) and temozolomide (Temodal) 21 June 2004 June 2007 Selective
There are also a number of appraisals of cancer drugs on NICE's work programme on which guidance has not yet been issued. The following table lists all the technology appraisals relating to cancer treatments, including the date of referral, the condition and the drugs appraised, whether they are being appraised as a Single Technology Appraisal (STA) or Multiple Technology Appraisal (MTA), the status of the appraisal and where available the expected date of issue.
STA/MTA Condition and drugs appraised Referral date Status Expected date of issue STA breast cancer (advanced or metastatic)—lapatinib (Tyverb) 19 December 2006 — TBC STA colon cancer (adjuvant)—irinotecan (Campto) 16 June 2004 (transferred to STA programme August 2006) Suspended: Campto is not currently licensed in the United Kingdom for this indication. TBC STA non-Hodgkin's lymphoma—rituximab (MabThera) Review of TA37 5 April 2005 — December 2007 STA glioblastoma multiforme (recurrent)—carmustine implants (Gliadel) 21 June 2004 (transferred to STA programme August 2006) — January 2008 STA head and neck cancer—cetuximab (Erbitux) 21 June 2004 Three appeals have been made against the Final Appraisal Determination. To be confirmed—subject to outcome of appeals. STA lung cancer (non small cell)—bevacizumab (Avastin) 19 December 2006 — January 2008 STA lung cancer (non small cell)—erlotinib (Tarceva) 5 April 2005 (transferred to STA programme November 2005) NICE awaits the decision of the appeal hearing heard on 6 June 2007. To be confirmed—subject to outcome of appeals. STA lung cancer (non small cell)—pemetrexed (Alimta) 5 April 2005 (transferred to STA programme November 2005) NICE awaits the decision of the appeal hearing heard on 6 June 2007. To be confirmed—subject to outcome of appeals. MTA lung cancer (non small cell)—gefitinib (Iressa) 1 April 2003 Suspended: Iressa is not currently licensed in the UK for this indication. To be confirmed MTA mesothelioma—pemetrexed disodium 21 June 2004 — September 2007 STA relapsed multiple myeloma—bortezomib (Velcade) 21 July 2005 (transferred to STA programme November 2005) — To be confirmed STA pancreatic cancer—Rubetican 21 June 2004 (transferred to STA programme November 2005) Suspended: The manufacturers have withdrawn their licence application. To be confirmed STA prostate cancer (hormone refractory)—Atrasentan 21 June 2004 (transferred to STA programme November 2005) Suspended: Atrasentan is not currently licensed in the UK for this indication. To be confirmed STA breast cancer—bevacizumab (Avastin) 19 June 2007 — To be confirmed MTA renal cell carcinoma—bevacizumab (Avastin), sorafenib tosylate (Nexavar) and sunitinib (Sutent) 19 June 2007 — To be confirmed